TellBio Logo.png
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
March 27, 2024 08:34 ET | TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223...
TellBio Logo.png
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
March 27, 2024 08:00 ET | TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for...
NVIDIA Healthcare Microservices
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health
March 18, 2024 17:16 ET | NVIDIA
SAN JOSE, Calif.—GTC, March 18, 2024 (GLOBE NEWSWIRE) -- NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Global Vision Transformers Market
Global Vision Transformers Industry Research 2023-2028 - Growing Impact of AI in Machine Vision Fuels Expansion of the Market
February 13, 2024 09:59 ET | Research and Markets
Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The "Global Vision Transformers Market by Offering (Solutions, Professional Services), Application (Image Segmentation, Object Detection, Image Captioning),...
Global Elastography Imaging Market
Elastography Imaging Market Poised for Robust Growth: Comprehensive Research Forecasts a CAGR of 7.91% from 2024 to 2034
January 29, 2024 05:01 ET | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Elastography Imaging Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. In an era where...
Global Healthcare Data Annotation Tools Market
Healthcare Data Annotation Tools Research Report 2023: A Global $900+ Million Market by 2030 Featuring Infosys, Shaip, Innodata, Ango AI, Capestart, Lynxcare, iMerit, Anolytics, V7, & SuperAnnotate
November 14, 2023 03:53 ET | Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Healthcare Data Annotation Tools Market Size, Share & Trends Analysis Report By Type (Text, Audio), By Technology (Manual, Automatic), By End-user,...
Oncternal.png
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
October 25, 2023 09:00 ET | Oncternal Therapeutics
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal.png
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
August 10, 2023 16:01 ET | Oncternal Therapeutics
Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor...
Oncternal.png
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
August 03, 2023 16:05 ET | Oncternal Therapeutics
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...